Evidence map›Paper›PMID 39119746›Full record

ArticleCancer medicine2024

phi and phiD predict adverse pathological features after radical prostatectomy for prostate cancer in Chinese population.

Ruofan Shi, Da Huang, Jiaqi Yan, Xiaohao Ruan, Jingyi Huang, Jiacheng Liu, Jinlun Huang, Yongle Zhan, Chi Yao, Tsun Tsun Stacia Chun and 5 more

Abstract read
In one paragraph

Article in Cancer medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Ruofan ShiDepartment of Urology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Da HuangDepartment of Urology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Jiaqi YanDepartment of Urology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Xiaohao RuanDepartment of Urology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.ORCID 0000-0001-8373-5237
Jingyi HuangDepartment of Urology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Jiacheng LiuDepartment of Urology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Jinlun HuangDepartment of Urology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Yongle ZhanDivision of Urology, Department of Surgery, School of Clinical Medicine, LKS School of Medicine, The University of Hong Kong, Hong Kong, China.
Chi YaoDivision of Urology, Department of Surgery, School of Clinical Medicine, LKS School of Medicine, The University of Hong Kong, Hong Kong, China.
Tsun Tsun Stacia ChunDivision of Urology, Department of Surgery, School of Clinical Medicine, LKS School of Medicine, The University of Hong Kong, Hong Kong, China.
Brian Sze-Ho HoDivision of Urology, Department of Surgery, School of Clinical Medicine, LKS School of Medicine, The University of Hong Kong, Hong Kong, China.
Ada Tsui-Lin NgDivision of Urology, Department of Surgery, School of Clinical Medicine, LKS School of Medicine, The University of Hong Kong, Hong Kong, China.
Yi GaoDepartment of Urology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Danfeng XuDepartment of Urology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Rong NaDivision of Urology, Department of Surgery, School of Clinical Medicine, LKS School of Medicine, The University of Hong Kong, Hong Kong, China.ORCID 0000-0001-7470-5108

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAnticipating the postoperative pathological stage and potential for adverse features of prostate cancer (PCa) patients before radical prostatectomy (RP) is crucial for guiding perioperative treatment.

methodsA cohort consisting of three sub-cohorts with a total of 709 patients has been enlisted from two major tertiary medical centres in China. The primary assessment parameters for adverse pathological features in this study are the pathological T stage, the AJCC prognostic stage groups and perineural invasion (PNI). Logistic regression analyses were performed to investigate the relationship between prostate specific antigen (PSA), its derivatives (incluing Prostate Health Index, phi and phi density, phiD), and the pathological outcomes after RP.

resultsBoth phi and phiD showed a significant association with pathologic T stage of pT3 or above (phi, adjusted OR, AOR = 2.82, 95% confidence interval, 95% CI: 1.88-4.23, p < 0.001; phiD, AOR = 2.47, 95% CI: 1.76-3.48, p < 0.001) and PNI (phi, AOR = 2.15, 95% CI: 1.39-3.32, p < 0.001; phiD, AOR = 1.94, 95% CI: 1.38-2.73, p < 0.001). In a subgroup analysis with a total PSA value <10 ng/mL, phi and phiD continued to show a significant correlation with pT3 or above (phi, AOR = 4.70, 95% CI: 1.29-17.12, p = 0.019; phiD, AOR = 3.44, 95% CI: 1.51-7.85, p = 0.003), and phiD also maintained its predictive capability for PNI in this subgroup (AOR = 2.10, 95% CI: 1.17-3.80, p = 0.014). Sensitivity analysis indicated that the findings in the combined cohort are mainly influenced by one of the sub-cohorts, partially attributable to disparities in sample sizes between sub-cohorts. Combined analysis of phi(D) and multiparametric MRI (mpMRI) data yielded similar results.

conclusionsPreoperative measurement of serum phi and phiD is valuable for predicting the occurrence of adverse pathological features in Chinese PCa patients after RP.

Indexed as

Neoplasm StagingProstatectomyProstatic NeoplasmsAgedChinaEast Asian PeopleHumansMaleMiddle AgedPrognosisProstate-Specific AntigenProstate-Specific Antigenpathological outcomesphi densityprostate cancerProstate Health Indexradical prostatectomy

Identifiers

PMID39119746
PMCPMC11310664

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.